3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
5
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Sarcoma
1
Head & Neck
1
Genitourinary
1
CNS
1
Conditions
Gastrointestinal Stromal Tumors
17
Sarcoma
6
Sarcoma, Ewing
5
Osteosarcoma
5
Neoplasm Metastasis
4
Rhabdomyosarcoma
3
Colorectal Neoplasms
3
Mesothelioma, Malignant
2
Hemangiosarcoma
2
Chondrosarcoma
2
Bone Neoplasms
2
Wilms Tumor
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thymoma
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Piebaldism
1
Patient Compliance
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Interventions
Cyclophosphamide
20
pembrolizumab
19
Nivolumab
10
fludarabine
7
Radiosurgery
7
Specimen Handling
6
Ipilimumab
6
Injections
5
Celecoxib
5
poly ICLC
4
Radiation
4
Paclitaxel
4
Melphalan
4
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Docetaxel
4
Cryosurgery
4
durvalumab
3
cemiplimab
3
Filgrastim
3
Etoposide
3
Cisplatin
3
Blood Specimen Collection
3
Biopsy
3
trastuzumab deruxtecan
2
tislelizumab
2
talimogene laherparepvec
2
spartalizumab
2
fludarabine phosphate
2
bempegaldesleukin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
regorafenib
×
Sarcoma
×
Clear all
NCT02307500
2022-09-10
RESOUND
Istituto Clinico Humanitas
Phase 2
Completed
82 enrolled